U.S. Blood Pressure and Temperature Monitors Markets

Frost & Sullivan
March 1, 2001
SKU: MC463599
License type:
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors  |  more...
$3,995.00
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is  |  more...
$5,175.00
Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is  |  more...
$5,175.00
Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria  |  more...
$5,175.00
Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized  |  more...
$5,175.00
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is  |  more...
$5,175.00
Triple Analysis: Leukemia, Apoptosis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria  |  more...
$5,175.00
Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria  |  more...
$5,175.00
Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in  |  more...
$5,175.00
Triple Analysis: Lymphoma, Pancreatic Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria  |  more...
$5,175.00